文献速递间质性肺疾病

肥大细胞类胰蛋白酶释放促进淋巴管肌瘤病进展

Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

淋巴管肌瘤病(LAM)中肥大细胞聚集机制不明。研究发现LAM细胞/成纤维细胞相互作用通过CXC趋化因子招募肥大细胞,肥大细胞释放类胰蛋白酶促进成纤维细胞增殖和LAM球体增大;色甘酸钠(SCG)可减少小鼠模型肿瘤负荷,提示SCG或可辅助mTOR抑制剂治疗。

要点

  • LAM结节周围肥大细胞与肺功能下降速率正相关。
  • 类胰蛋白酶抑制剂APC366和SCG抑制肥大细胞诱导的球体生长。
  • SCG在Tsc2-null小鼠模型中减少肿瘤负荷,支持其用于LAM的再定位研究。

核心结论

  • LAM细胞与成纤维细胞相互作用招募肥大细胞,肥大细胞释放类胰蛋白酶促进疾病进展。
  • SCG可作为mTOR抑制剂治疗的替代或辅助方案进一步研究。

研究设计与样本

  • 研究采用转录组分析和qRT-PCR检测基因表达。
  • 体外使用球体TSC2-null细胞/成纤维细胞共培养,体内使用免疫健全Tsc2-null小鼠同种移植模型。

主要发现

  • LAM来源的细胞/成纤维细胞共培养诱导成纤维细胞产生多种CXC趋化因子。
  • LAM肺组织中类胰蛋白酶阳性肥大细胞增多且表达CXCRs(P < 0.05)。
  • 位于LAM结节周围的肥大细胞与肺功能下降速率正相关(P = 0.016)。
  • LAM球体吸引肥大细胞,该过程可被CXCR1和CXCR2的药理学和CRISPR/cas9抑制所阻断。
  • LAM球体诱导肥大细胞类胰蛋白酶释放,促进成纤维细胞增殖并使LAM球体增大(1.36 ± 0.24倍;P = 0.0019)。

关键数值与推荐

  • 类胰蛋白酶抑制剂APC366和色甘酸钠(SCG)抑制肥大细胞诱导的球体生长。
  • 体内实验中SCG减少肥大细胞活化和Tsc2-null肺肿瘤负荷(溶剂组:32.5.3% ± 23.6%;SCG组:5.5% ± 4.3%;P = 0.0035)。

临床怎么用

  • SCG可能作为LAM患者mTOR抑制剂治疗的替代或辅助方案,需进一步临床研究。
  • 靶向肥大细胞类胰蛋白酶或CXCR1/CXCR2通路可能成为LAM治疗新策略。

局限性

  • 研究主要基于体外共培养和动物模型,人体证据有限。
  • SCG在LAM患者中的疗效和安全性尚未验证,需临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Lymphangioleiomyomatosis (LAM) is a multisystem disease that causes lung cysts and respiratory failure. Loss of TSC (tuberous sclerosis complex) gene function results in a clone of "LAM cells" with dysregulated mTOR (mechanistic target of rapamycin) activity. LAM cells and fibroblasts form lung nodules that also contain mast cells, although their significance is unknown. Objectives: To understand the mechanism of mast-cell accumulation and the role of mast cells in the pathogenesis of LAM. Methods: Gene expression was examined using transcriptional profiling and qRT-PCR. Mast cell/LAM nodule interactions were examined in vitro using spheroid TSC2-null cell/fibroblast cocultures and in vivo using an immunocompetent Tsc2-null murine homograft model. Measurements and Main Results: LAM-derived cell/fibroblast cocultures induced multiple CXC chemokines in fibroblasts. LAM lungs had increased tryptase-positive mast cells expressing CXCRs (CXC chemokine receptors) (P < 0.05). Mast cells located around the periphery of LAM nodules were positively associated with the rate of lung function loss (P = 0.016). LAM spheroids attracted mast cells, and this process was inhibited by pharmacologic and CRISPR/cas9 inhibition of CXCR1 and CXCR2. LAM spheroids caused mast-cell tryptase release, which induced fibroblast proliferation and increased LAM-spheroid size (1.36 ± 0.24-fold; P = 0.0019). The tryptase inhibitor APC366 and sodium cromoglycate (SCG) inhibited mast cell-induced spheroid growth. In vivo, SCG reduced mast-cell activation and Tsc2-null lung tumor burden (vehicle: 32.5.3% ± 23.6%; SCG: 5.5% ± 4.3%; P = 0.0035). Conclusions: LAM-cell/fibroblast interactions attract mast cells where tryptase release contributes to disease progression. Repurposing SCG for use in LAM should be studied as an alternative or adjunct to mTOR inhibitor therapy.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Babaei-Jadidi R, Dongre A, Miller S, et al. Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2021. PMID: 33882264. doi:10.1164/rccm.202007-2854OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。